Skip to main content

Clinical Trials Using Venetoclax

Review the clinical trials studying venetoclax on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 156

Testing Early Treatment for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Status: Active
Location: 492 locations
Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Status: Active
Location: 221 locations
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients with High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Status: Active
Location: 211 locations
Comparing Cytarabine + Daunorubicin Therapy versus Cytarabine + Daunorubicin + Venetoclax versus Venetoclax + Azacitidine in Younger Patients with Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Status: Active
Location: 167 locations
Comparing New Treatments for People with Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Status: Active
Location: 113 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 107 locations
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Status: Active
Location: 112 locations
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients with Relapsed and/or Refractory Aggressive B-cell Lymphoma
Status: Active
Location: 82 locations
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Status: Active
Location: 34 locations
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Status: Active
Location: 28 locations
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Status: Active
Location: 19 locations
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Status: Active
Location: 21 locations
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Status: Active
Location: 19 locations
Venetoclax for the Treatment of Patients with Relapsed Hairy Cell Leukemia
Status: Active
Location: 21 locations
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Active
Location: 17 locations
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Status: Active
Location: 18 locations
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Status: Active
Location: 17 locations
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Active
Location: 15 locations
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Status: Active
Location: 15 locations
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Status: Active
Location: 13 locations
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Status: Active
Location: 11 locations
Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Status: Active
Location: 10 locations
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: 9 locations
Zanubrutinib, Obinutuzumab, and Venetoclax in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Mantle Cell Lymphoma
Status: Active
Location: 9 locations
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 11 locations